Antibody responses after two-doses of inactivated vaccine followed by a booster dose of either viral-vector or mRNA COVID-19 vaccine in healthcare workers in Nakhon Phanom Hospital
Keywords:
Covid-19 vaccine, Third dose booster, Health care workerAbstract
Objective: To compare immunogenicity of a booster viral-vector or mRNA COVID-19 vaccine after received two-dose inactivated vaccines in health care workers (HCWs) in Nakhon Phanom hospital.
Methods: We conducted concurrent observational therapeutic research study in Nakhon Phanom hospital. The participants were 100 HCWs who received two-dose of inactivated vaccine; Sinovac and were going to receive third dose between June and August 2021. We compared immunogenicity between 50 HCWs who received AZD1222 (ChAdOx1 nCoV19 vaccine, Oxford-AstraZeneca) and 50 HCWs who received BNT162b2 (BNT162b2 vaccine, Pfizer-BioNTech). Sera were tested for SARS-CoV-2 total Ig by sandwich qualitative ELISA (Wantai Biological Pharmacy, Beijing) and microneutralization (microNT) assay against Delta variant
Results: HCWs were female in 86% and 80%, median age was 45 years (IQR 34-52) and 36 years (IQR 31-42) (p < 0.001) in AZD1222 and BNT162b2 group, respectively. In baseline sera, 100% of both groups were positive for SARS-CoV-2 antibodies by ELISA. At 4 weeks after the booster, the mean total Ig values were 16.48±0.41and 16.67±0.49 in the AZD1222 group and BNT162b2 group, respectively (p=0.75). In baseline sera, the GMNT were 5.74 (5.13, 6.43) and 6.10 (5.30, 7.01) (p = 0.663); 4 weeks after booster vaccination, GMNT increased to 54.26 (42.18, 68.80) and 190.27 (153.75, 253.47) (p < 0.001). After adjusted for age and duration from 2nd dose to booster 3rd dose, proportions of 4-fold rise in antibody titers of 90% (78.2, 97.2) and 100% (93.6, 100.0) (p = 0.882) in the AZD1222 group and BNT162b2 group, respectively.
Conclusion: This study demonstrated neutralizing antibody activity against Delta variant in HCWs who completed two doses of inactivated vaccine and one booster dose with either viral-vectored or mRNA vaccine. Further study is needed to determine the effect of the booster dose on clinical outcomes and with other variants.
References
World Health Organization. WHO Coronavirus (COVID-19) Dashboard, Cases [Internet]. 2020 [cited 2022 Nov 9]. Available from: https://covid19.who.int/?mapFilter=cases
World Health Organization. WHO Coronavirus (COVID-19) Dashboard, Vaccination [Internet]. 2020 [cited 2022 Nov 9]. Available from: https://covid19.who.int/?mapFilter=vaccinations
Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. Vaccine 2022;40:524–530.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181–92.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99–111.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med 2021;384(20):1885–98.
Flight L, Julious SA. Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharmaceut Statist 2016;15:80–89.
Lerdsamran H, Mungaomklang A, Iamsirithaworn S, et al. Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand. BMC Infect Dis. 2021;21(1):1213. DOI: 10.1186/s12879-021-06921-y
Pan H, Wu Q, Zeng G, Yang J, Jiang D, Deng X, et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. medRxiv 2021 [preprint]. DOI: https://doi.org/10.1101/2021.07.23.21261026
Wang K, Cao Y, Zhou Y, Wu J, Jia Z, Hu Y, et al. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2. medRxiv 2021 [preprint]. DOI: https://doi.org/10.1101/2021.09.02.21261735
Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 2021;398(10304):981–90.
Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med 2021;385(13):1244-1246. DOI: 10.1056/NEJMc2111462
Wilder-Smith A, Mulholland K. Effectiveness of an Inactivated SARS-CoV-2 Vaccine. N Engl J Med 2021;385(10):946–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 The Office of Disease Prevention and Control 10th
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของ สำนักงานป้องกันควบคุมโรคที่ 10 จังหวัดอุบลราชธานี
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับสำนักงานป้องกันควบคุมโรคที่ 10 จังหวัดอุบลราชธานีและบุคลากรท่านอื่นๆในสำนักงานฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
